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morphine intravenous patient-controlled analgesia (IV PCA) ease of
care (EOC) using a validated patient EOC questionnaire. Fentanyl ITS
is a preprogrammed, needle-free PCA system used for the management
of acute pain in postoperative patients.
Methods: This meta-analysis assessed the patient EOC of fentanyl ITS and
morphine IV PCA using data from three randomized, active-comparator
trials in adult postoperative patients with moderate-to-severe pain. All
three studies utilized a validated patient EOC questionnaire which con-
sists of 23 items grouped into seven subscales (confidence with device,
comfort with device, movement, dosing confidence, pain control, knowl-
edge/understanding, and satisfaction). Each item is scored on a six-point
Likert scale. The weightedmean difference between treatments was calcu-
lated for the overall EOC and for each of the seven subscales.
Results: The EOC analyses were based on responses to questionnaires
from 1,943 patients treated with either fentanyl ITS (n 5 961) or
morphine IV PCA (n 5 982). There was a statistically significant advan-
tage in favor of fentanyl ITS overmorphine IV PCA in terms of overall EOC
(weighted mean difference 5 0.28; 95% confidence interval (0.22 to
0.34); P , 0.0001). Five of the seven subscales (confidence with device,
comfort with device, movement, dosing confidence, and knowledge/un-
derstanding) on the patient EOC questionnaire showed a statistically sig-
nificant advantage for fentanyl ITS versus morphine IV PCA. The two
subscales that did not show any difference were pain control (P 5
0.7303) and satisfaction (0.0561).
Conclusion: In this meta-analysis, fentanyl ITS is associatedwith some ad-
vantages in terms of an EOC profile from a patients’ perspective when
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 2016 by American Society of PeriAnesthesia NursesEFFECTIVE POSTOPERATIVE PAIN MANAGE-
MENT is critical to successful outcomes including
early mobilization, increased patient satisfaction,
and reduced hospital stay and costs.1 Conversely,
ineffective postoperative pain management can
have some long-term consequences including
the development of chronic pain.2 Patient-
controlled analgesia (PCA) is commonly used to
treat postoperative pain as part of a multimodal
treatment regimen.3,4 However, with either
intravenous (IV) or epidural PCA systems, there
are potential pitfalls which include reduced
mobilization as the patient is connected to the
PCA pump and the potential for programming
errors.5-9
Fentanyl iontophoretic transdermal system (ITS)
is a noninvasive PCA system that is utilized for
the treatment of postoperative pain (Figure 1).
Fentanyl ITS is a preprogrammed, needle-free de-
livery system that utilizes iontophoresis whereby
the drug is delivered through the skin via a nearly
imperceptible electric current.10 The health care
provider assembles the system by snapping the
controller (the top half of the device containing
all electronics) and drug unit (the bottom halfstration of the fentanyl ITS controller
and assembled system. The device is
he size of a credit card. The controller
e assembled by the health care profes-
ely before application. ITS, iontopho-
al system. This figure is available in
ww.jopan.org. Reprintedwith permis-
edicines Company (Parsippany, NJ).containing the 10.8 mg of fentanyl HCl) together
immediately before application to the patient.
The system is held on the skin with adhesive. Fen-
tanyl ITS delivers a preprogrammed analgesic
dose based on the patients control. The use of fen-
tanyl ITS reduces the need for venous access for
pain management, eliminates the potential for
programming errors, and minimizes the potential
for medication errors.11 In addition, staff time
spent on PCA administration may be reduced
with the fentanyl ITS and therefore can be utilized
for direct patient care.12,13 Postoperative patient
mobility is essential to recovery and is important
for preventing complications after major
surgery.14 Fentanyl ITS has the potential to in-
crease patients’ mobility since no IV or epidural
lines or equipment such as pumps and poles are
needed for analgesia.
The efficacy and safety of fentanyl ITS have been
well studied. In four phase 3B randomized,
active-comparator trials, fentanyl ITS demon-
strated an equal efficacy and similar safety profile
to morphine IV PCA.15-18 From a dosing
perspective, in the phase 3B trials, a fentanyl ITS
40 mcg dose over 10 minutes for up to six doses/
hour was approximately equianalgesic with
morphine IV PCA 1-mg morphine bolus doses for
up to 10 doses/hour with a 5- or 6-minute lockout
periods between doses.
A previous report on the patients’ perspective of
ease of care (EOC) has been reported using data
from two of the phase 3B studies.19 That analysis
was performed using a simple pooled analysis tech-
nique (ie, the analysis was performed as if the data
were derived from a single sample). In this current
analysis, we are using data from three of the four
phase 3B trials (the fourth study did not collect
thepatient EOCquestionnaire), andweareutilizing
a meta-analytic technique. Meta-analysis allows
detection of treatment effects with greater power
andestimates these effectswith greaterprecision.20
This report represents the first ever conducted
meta-analysis comparing fentanyl ITS with
morphine IVPCAEOC fromapatients’ perspective.
Table 1. Baseline Characteristics and Disposition, Treated Population
Characteristic
Study 115: Europe Study 216: United States Study 317: United States
Fentanyl
ITS; N 5 325
Morphine IV
PCA; N 5 335
Fentanyl
ITS; N 5 395
Morphine IV
PCA; N 5 404
Fentanyl
ITS; N 5 252
Morphine IV
PCA; N 5 254
Mean age, y (SD) 53.5 (14.5) 53.0 (14.58) 62.8 (11.98) 62.9 (12.34) 50.2 (14.07) 50.4 (13.93)
Female, n (%) 186 (57.2) 191 (57.0) 206 (52.2) 208 (51.5) 212 (84.1) 213 (83.9)
Surgery type




79 (24.3) 111 (33.1) 395 (100) 404 (100) — —
Pelvic 42 (12.9) 39 (11.6) — — 159 (63.1) 173 (68.1)
Other 56 (17.2) 58 (17.3) — — — —
Body mass index,
kg/m2, mean





$ 3 h), n
322 334 389 397 250 251
Completed study, n 288 298 333 347 210 224
ITS, iontophoretic transdermal system; IV PCA, intravenous patient-controlled analgesia; NA, not available; SD, stan-
dard deviation.
Treated population included any patients that received study treatment.
COMPARING FENTANYL ITS VS MORPHINE IV PCA 3Methods
PubMed, Cochrane Library, and Google Scholar
were searched combining the terms ‘‘fentanyl’’Figure 2. Patient Ease-of-Care Questionnaire. Adapted fr
2010; 13(1):42-54.and ‘‘iontophoretic’’ and ‘‘ease of care’’ for the
period of 1980 to August 1, 2015. Studies were
included if they studied fentanyl ITS and had
used the validated patient EOC questionnaire.21om Harding G et al. Journal of Medical Economics.
Figure 3. Mean scores for patient overall EOC. Weighted means difference and P value were based on random
effect model for meta-analysis. Overall EOC score was calculated as mean of subscale scores. Higher difference
means ‘‘favors fentanyl ITS.’’ EOC, ease of care; CI, confidence intervals; ITS, iontophoretic transdermal system;
IV PCA, intravenous patient-controlled analgesia; SD, standard deviation; WMD, weighted mean difference.
4 LINDLEY ET ALThe manufacturer also provided information
regarding their phase 3B clinical studies. One
pooled analysis that detailed the results of two
studies was included from the literature,19 and
one study was included from the manufacturer.
The manufacturer indicated that only three studies
in the clinical development program had utilized
the validated patient EOC questionnaire. All data
relating to the patient EOC questionnaire were
provided by the manufacturer relating to these
three studies. At the time that the meta-analysis
was conducted, fentanyl ITS was not commercially
available, and therefore no additional studies could
have been performed. Therefore, all studies that
had been conducted with fentanyl ITS and utilized
the validated patient EOC questionnaire were
included.
A meta-analysis was conducted using data from all
of the active-comparator phase 3B studies that
compared fentanyl ITS with morphine IV PCA
and utilized the validated patient EOC question-
naire.15-17 Details of the studies are included in
Table 1. In these studies, patients were randomly
assigned to receive either fentanyl ITS or morphine
IV PCA. Patients in the fentanyl ITS group received
a 40-mcg dose over 10 minutes for up to six doses/
hour for 24 hours or a maximum of 80 doses per
system (whichever occurred first), after which a
new system could be applied if needed. Patients
treated with morphine IV PCA received 1-mgmorphine bolus doses for up to 10 doses/hour
with a 5- or 6-minute lockout periods between
doses (depending upon site-specific polices) for
24 hours (up to a maximum of 240 doses).
The patient EOC questionnaire is a validated tool
which consists of 23 items grouped into seven sub-
scales (confidence with device, comfort with
device,movement, dosingconfidence,paincontrol,
knowledge/understanding, and satisfaction;
Figure 2). All items, with the exception of the satis-
faction items,were scoredon a six-point Likert scale
(0 5 not at all; 1 5 a little bit; 2 5 somewhat; 3 5
quite a bit; 4 5 a great deal; and 5 5 a very great
deal; Figure 2). The satisfaction items were scored
on a six-point Likert scale (0 5 extremely dissatis-
fied; 15 very dissatisfied; 25 dissatisfied; 35 satis-
fied; 45 very satisfied; and 55 extremely satisfied;
Figure 2). During the analysis, items 1 to 5, 10, and
13 to21were transformed so thathigher scores indi-
cated more favorable results on the questionnaire.
Statistical Analysis
The meta-analysis was conducted using random ef-
fects model which is a conservative statistical
method.22 Analyses using random effects models
assume that the results are to be generalized to
the entire patient population and have been previ-
ously used in Cochrane evaluations. The software
used in the statistical analysis was SAS, version 9.3.
Figure 4. Mean scores for patient EOC subscales. Weighted means difference and P value were based on random
effectmodel for meta-analysis. Overall EOC scorewas calculated asmean of subscale scores. Each subscale scorewas
average of nonmissing items comprising subscale. Higher difference means ‘‘favors fentanyl ITS.’’ EOC, ease of care;
CI, confidence intervals; ITS, iontophoretic transdermal system; IV PCA, intravenous patient-controlled analgesia;
WMD, weighted mean difference.
COMPARING FENTANYL ITS VS MORPHINE IV PCA 5Weighted mean scores were calculated for each
individual item in the questionnaire and for the
overall EOC as well as the subscales. During the
analysis, we integrated patient EOC questionnaire
data of 23 items from three active-controlled
studies with items 1 to 5, 10, and 13 to 21 trans-
formed so that higher scores indicated more
favorable results on the questionnaire. In addition
to evaluating mean scores, post hoc analyses
were completed evaluating responders. A
responder for each of the six subscales included
in the overall EOC (satisfaction was not included)
was defined as a patient who responded with one
of the three most positive choices of the Likert
scale on all items of a subscale. A responder for
overall EOC was defined as a patient who re-
sponded with one of the three most positive
choices for all 21 items in the six subscales
included in the overall EOC calculations (ie, con-
fidence with dosing, comfort with device, move-
ment, dosing confidence, pain control, andknowledge/understanding subscales). A responder
on the satisfaction subscale was defined as a pa-
tient who responded with one of the two most
positive choices of the Likert scale on both items
of the subscale.
For continuous variables, the weighted mean differ-
ence (WMD) between treatments was calculated.
For dichotomous variables, odds ratios (ORs) indi-
cating the probability of the outcome to occur for
a patient receiving fentanyl ITS versus morphine
IV PCA were calculated. Statistical tests were per-
formed at the .05 significance level, with no multi-
plicity adjustments. Ninety-five percent confidence
intervals (CIs) were provided for all parameters.
Results
Three phase 3B studies in the fentanyl ITS develop-
ment program measured patient EOC via a vali-
dated questionnaire, and a total of 1,965 patients
Figure 5. Analysis of EOC from patients by item (mean score). Weightedmeans difference and P valuewere based
on random effect model for meta-analysis. Higher difference means ‘‘favors fentanyl ITS’’. During the analysis, items
1-5, 10, and 13-21 were transformed, so that higher scores indicated more favorable results on the questionnaire.
EOC, ease of care; CI, confidence intervals; ITS, iontophoretic transdermal system; IV PCA, intravenous patient-
controlled analgesia; WMD, weighted mean difference.
6 LINDLEY ET ALwere included in this analysis. The mean age of pa-
tient ranged from 50.2 years to 62.9 years
(Table 1). In the studies that measured body mass
index, the mean was between 29.2 and 29.8 kg/
m2. The majority (86.5%) of patients completed
the study (Table 1).
Patient EOC
MEAN SCORE COMPARISONS. There was a sta-
tistically significant benefit in favor of fentanyl
ITS over morphine IV PCA in terms of the patients’
overall EOC (WMD 5 0.28 [95% CI: 0.22 to 0.34],
P , 0.0001; Figure 3). There was a statistically
significant benefit in favor of fentanyl ITS over
morphine IV PCA in terms of the five of the sevensubscales (confidence with device: WMD 5 0.14
[95% CI: 0.08 to 0.19], P , 0.0001; comfort with
device: WMD 5 0.10 [95% CI: 0.01 to 0.19], P 5
0.0382; mobility: WMD 5 1.02 [95% CI: 0.87 to
1.18], P , 0.0001; dosing confidence: WMD 5
0.14 [95% CI: 0.06 to 0.21], P 5 0.0002; knowl-
edge/understanding: WMD 5 0.23 to [95% CI:
0.12 to 0.35], P , 0.0001). There was no differ-
ence between the two groups in terms of pain
control (WMD 5 0.04 [95% CI: 20.19 to 0.27], P
5 0.7303) or satisfaction (WMD 5 0.14 [95% CI:
0.00 to 0.28], P 5 0.0561; Figure 4).
The WMD was also calculated for each item
(Figure 5). There was a statistically significant
WMD in favor of fentanyl ITS for 14 of the 23 items.
Figure 6. Patient responder for subscales. Odds ratio and P value were based on random effect model for meta-
analysis. A responder for each of the six subscales included in the overall EOC (satisfaction was not included) was
defined as a patient who responded with one of the three most positive choices of the Likert scale on all items of
a subscale. A responder for overall EOC was defined as a patient who responded with one of the three most choices
for all 21 items in the six subscales included in the overall EOC calculations (ie, confidence with dosing, comfort with
device, movement, dosing confidence, pain control, and knowledge/understanding subscales). A responder on the
satisfaction subscale was defined as a patient who responded with one of the twomost positive choices of the Likert
scale on both items of the subscale. CI, confidence interval; ITS, iontophoretic transdermal system; IV PCA, intrave-
nous patient-controlled analgesia; OR, odds ratio.
COMPARING FENTANYL ITS VS MORPHINE IV PCA 7There were no items where morphine IV PCAwas
favored over fentanyl ITS.
RESPONDERDATA. Significantly greater percent-
ages of patients were considered responders in the
fentanyl ITS group (37.9%) compared to the
morphine IV PCA group (26.4%) for the patient
overall EOC (OR: 1.689 [1.293, 2.208], P 5
0.0001; Figure 6). There were also significantly
greater percentages of patients who were consid-
ered responders in the fentanyl ITS group
compared to the morphine IV PCA group in five of
the seven subscales including confidence with
device, mobility, dosing confidence, knowledge/
understanding, and satisfaction (Figure 5). There
was no difference in either the comfort with de-
vice or pain control subscales in terms of re-
sponders.
Discussion
In this meta-analysis, there was a statistically signif-
icant difference in favor of fentanyl ITS overmorphine IV PCA in terms of overall EOC from
the patients’ perspective. For five of the seven sub-
scales (confidence with device, comfort with the
device, mobility, dosing confidence, and knowl-
edge/understanding), fentanyl ITS was statistically
significantly superior to morphine IV PCA; in the
remaining two subscales (pain control and satisfac-
tion), therewas no difference between treatments.
Similar results were obtained when a responder
analysis was completed. The only difference be-
tween the WMD analysis and the responder anal-
ysis was that there was no difference in comfort
with device in the responder analysis although
there had been in the WMD analysis and satisfac-
tion statistically significantly favored fentanyl ITS
over morphine IV PCA in the responder analysis.
In both analyses, pain control was equivalent be-
tween the two treatments.
Mobility is very important for patients especially in
terms of ambulation. Each of the mobility subscale
items and the mobility subscale showed a statisti-
cally significant difference in favor of fentanyl ITS
8 LINDLEY ET ALtreatment versus morphine IV PCA treatment. The
items include both mobility in the bed and ambu-
lation out of the bed. Postoperative patient
mobility is one of the most important factors for
preventing complications after major surgery
(including, but not limited to pneumonia, pulmo-
nary embolus, deep vein thrombosis, urinary tract
infection).23-26 Early mobilization is also important
in improving the quality of care and reducing
length of stay in the hospital.24,26,27 In addition,
early patient mobility/ambulation is one of the
key principles of enhanced recovery after
surgery protocols.28,29
While the satisfaction subscale analysis was not sta-
tistically significant (WMD5 0.14 [95% CI: 0.00 to
0.28], P 5 0.0561), the number of patients who
were responders on the satisfaction subscale did
show a statistically significant difference in favor
of fentanyl ITS (fentanyl ITS: 75.3% vs morphine
IV PCA 69.0%; OR: 1.366 [95% CI: 1.15 to 1.675],
P 5 0.0026).
Extensive patient testing determining ease of use
has been completed with the fentanyl ITS system
in the form of human factors studies.30 The major-
ity of patients in these studies found the system
very easy to use with very little training. This
finding is confirmed in this study as both subscalesin the patient EOC that specifically deal with
handling of the device (ie, confidence with device
and dosing confidence) showed statistically signif-
icant differences in favor of fentanyl ITS over
morphine IV PCA. Therefore, the results of the hu-
man factors study and this meta-analysis demon-
strate that the fentanyl ITS system is easy to use
from the patients’ perspective.
Conclusion
These results show significant advantages for fen-
tanyl ITS over morphine IV PCA in terms of pa-
tients’ perspective of EOC. In this study,
patients found fentanyl ITS very easy to use.
There was a significant benefit seen in terms of
mobility which included both movement in the
hospital bed and ambulation in favor of fentanyl
ITS over morphine IV PCA. Fentanyl ITS offers
potential advantages from the patients’ perspec-
tive over traditional IV PCA while still obtaining
the same level of efficacy.Acknowledgments
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